TOKYO and WESTBOROUGH, Mass., Dec 15, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer, and more fulfilling, has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II. Building on the success of the initial fund, Olympus will deploy $150 million to invest in promising MedTech startup companies focused on Gastrointestinal (GI), Urology and Respiratory.Abigail Hunter-Syed, Head of OIV, speaking at The MedTech Conference 2025(photo courtesy of MedTech Innovator)OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A opportunities, partnerships, and valuable market insights. OIV is stage-agnostic, prioritizing early to growth-stage companies globally with therapeutic solutions for targeted medical specialties. In addition to capital, Olympus will continue to help its portfolio companies succeed by contributing its clinical and technical expertise, access to healthcare professionals and hospitals, and ability to launch and scale innovative solutions in the global market.OIV focuses on investments in passionate founders who are revolutionizing medical solutions. The fund invests in customer-driven solutions in medical devices, diagnostics and digital health. Since its inception in October 2021, OIV has made nine investments in areas such as AI workflow solutions and medical imaging agents for cancer detection.Bob White, Director, Representative Executive Officer, President and Chief Executive Officer at Olympus, said, “Our expanded venture fund commitment reflects Olympus’ deep dedication to innovation and growth. By supporting visionary innovators and breakthrough technologies over time, we aim to accelerate solutions that improve patient outcomes and strengthen our leadership in MedTech.”Cerity Partners Ventures (Cerity), a firm specializing in corporate venture capital, will continue to help manage the Olympus venture fund. Cerity will work closely with senior executives of Olympus in all aspects of operating the fund."The Cerity Partners Ventures team is excited to continue working with Olympus, leveraging our collective technical strengths, industry relationships, and subject matter expertise to fund and support leading entrepreneurs,” noted Kindra Tatarsky, Partner at Cerity Partners Ventures. “This fund will build on Olympus Innovation Ventures’ mission to be the partner of choice for innovators, creating a competitive advantage for their startups."Gabriela Kaynor, Executive Officer and Chief Strategy Officer at Olympus and Chair of the OIV Investment Committee, said, “With an additional commitment to corporate venture capital, we will continue to make investments in startup teams who are building unique solutions in endoscopy-enabled care. Olympus Innovation Ventures investments help accelerate our progress toward developing the endosuite of the future with capabilities for early detection, diagnosis, and advanced therapies powered by AI, robotics, and beyond.”Olympus remains committed to strengthening its market leadership through innovation, strategic partnerships, and investment in breakthrough technologies. Moving forward, OIV will continue to support Olympus’ commitment to elevating unique capabilities and drive growth in the global MedTech ecosystem.For more information, please visit: olympusamerica.com/olympus-innovation-ventures or email: ventures@olympus.com.About Cerity Partners VenturesCerity Partners Ventures partners with corporations to help launch and manage their venture capital programs. CPV works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm is a Registered Investment Adviser and maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on CPV can be found at https://ceritypartners.com/corporations/corporate-venture-capital/About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global LinkedIn accounts.Media contact:Mail: Global-Public_Relations@olympus.comOlympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
(SeaPRwire) - 当局称,周日晚上在邦迪海滩举行光明节庆祝活动期间发生的大规模枪击事件,造成至少16人死亡,40人住院。这项名为“海边光明节”的年度庆祝活动原定于下午5点开始,通过点燃烛台上的第一支蜡烛来庆祝犹太节日的首日。警方称,此次袭击“针对”了犹太社区,并正作为恐怖主义行为进行调查。New South Wales Police Force (NSWPF) 表示,警员于周日下午6点45分左右接到枪击报告后赶到现场。警方称,至少有两名枪手参与了袭击,他们正在调查是否存在第三名枪手的可能性。警方称,当地时间周一上午,警方证实枪击事件已造成16人死亡,其中包括两名嫌疑枪手中的一人。第二名嫌疑枪手情况危急。该机构证实,枪击事件发生后,至少40人仍在住院,其中包括两名警员。这是自2023年10月7日哈马斯恐怖袭击以来,针对犹太人最严重的袭击。警方补充说,他们在袭击现场附近的一辆车中发现了多个简易爆炸装置的证据。他说:“我们目前有我们的救援排爆小组在那里处理此事。”在耶路撒冷一次表彰移民非凡成就的活动中发表讲话时,承认了此次袭击。赫尔佐格说:“就在此刻,我们澳大利亚悉尼的兄弟姐妹们在邦迪海滩点燃光明节第一支蜡烛时,遭到了卑鄙恐怖分子的残酷袭击。我们心系他们。整个以色列民族的心脏此刻都为之停跳,我们为伤者康复祈祷,为他们祈祷,也为逝者祈祷。”赫尔佐格还呼吁澳大利亚政府“采取行动,打击困扰澳大利亚社会的巨大。”本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。
分类: 头条新闻,日常新闻
SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。